[Final recommendations to incorporate efalizumab into the clinical practice].
García-Díez
A
A
Hospital Universitario La Princesa, Universidad Autónoma de Madrid, España. agarcia@edv.es
Ferrándiz
C
C
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011364:Professional Practice; D011565:Psoriasis / Q000188:drug therapy / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D003879:Dermatologic Agents; C472181:efalizumab